Abbott Labs' (NYSE: ABT) upcoming spinoff company, AbbVie, is forefront on investors' minds at the moment, as it means the core company will lose its blockbuster drug Humira over to AbbVie. In this video, however, Motley Fool health-care analyst Brenton Flynn highlights some other preparations Abbott Labs is making ahead of the split, uncovered from the company's recent SEC filings, that show how Abbott may be streamlining the core business in a play to increase margins down the road.
Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
